Enhanced neutralizing antibody response induced by inactivated enterovirus 71 in cynomolgus monkeys

Hyun Ju In¹,²*, Heeji Lim¹,²*, Jung-Ah Lee¹, Sang-Rae Lee³, Yeung Bae Jin³, Kang-Jin Jeong³, Ji-Yeon Hyeon¹, Jung Sik Yoo¹, June-Woo Lee¹, Young Ki Choi², Sang-Won Lee¹

¹ Division of Vaccine Research, National Research Institute of Health, Centers for Disease Control and Prevention, Osong-eup, CheongJu, Chungcheongbuk-do, Republic of Korea, ² College of Medicine and Medical Research Institute, Chungbuk National University, CheongJu, Chungcheongbuk-do, Republic of Korea, ³ The National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology, Ochang-eup, CheongJu, Chungcheongbuk-do, Republic of Korea

These authors contributed equally to this work.

* epilsw@korea.kr

Abstract

Enterovirus 71 (EV71) is a major etiological agent of various public health issues, particularly in the Asia-Pacific region. EV71 causes hand-foot-and-mouth disease (HFMD) and is associated with serious neurological disorders in young children. A formalin-inactivated EV71 candidate vaccine (KCDC-HFMDV1-EV71) based on the C4 subgenotype was previously developed and confirmed to be a potential candidate vaccine for prevention of EV71 infection in mice. In this study, an inactivated EV71 vaccine was used for analysis of long-term immunogenicity and efficacy in cynomolgus monkeys, a common nonhuman primate model. The vaccine was immunized three times at 0, 4, and 8 weeks with either 20-μg doses of EV71 candidate vaccine formulated with aluminum hydroxide gel adjuvant or phosphate-buffered saline as a control. The group immunized with the inactivated EV71 showed significantly increased EV71-specific antibody and serum neutralizing antibody titers at 3 weeks after vaccination and maintained these elevated titers until the end of the experiment (54 weeks after vaccination). The sera from vaccinated cynomolgus monkeys showed a crossreactive neutralizing antibody response to the heterologous subtype of EV71 (B1–4, C1, and C2). These findings suggest that the inactivated EV71 candidate vaccine may be a potential vaccine candidate and valuable tool for the control of HFMD.

Introduction

Enterovirus 71 (EV71) infection has emerged as a serious threat to public health in young children worldwide [1]. EV71 belongs to the genus Enterovirus, family Picornaviridae. EV71 is a nonenveloped, single-stranded, positive-sense RNA virus and is classified into four genotypes, i.e., genotypes A, B, C, and D, based on the VP1 gene sequence. Genotypes A and D are represented by single strains, i.e., BrCr and India strains, respectively, whereas genotypes B and C...
were each divided five subgenotypes, designated B1–B5 and C1–C5. Genotypes B and C are distributed worldwide, whereas genotype A is much less common [2, 3]. Recombination events between genotypes of EV71 have generated a new subgenotype [4].

EV71 was identified as a major causative agent of hand-foot-and-mouth disease (HFMD) in 1969, when the virus was first isolated [5]. Outbreaks of EV71 infection have been reported frequently in the Asia-Pacific region, and the infection is associated with neurological disorders in children [6–8]. More than 80% of patients who die from HFMD with neurological symptom show EV71 infection [7, 9]. Diverse subgenotypes have been reported in HFMD outbreaks in Malaysia (B3 in 1997, B4 in 2000), Taiwan (C2 in 1998, B4 in 2000), Singapore (B4 in 2000), Vietnam (C5 in 2005), China (C4 from 2008), and Korea (C3 in 2000, C4 in 2009) [10].

The neutralizing antibody response is important for the prevention of EV71 infection and transmission [11]. Moreover, T-cell immune responses play a critical role in controlling the disease [12, 13]. Development of an ideal EV71 vaccine inducing both humoral and cellular immune responses is critical. Several types of EV71 vaccine candidates have been developed, including inactivated virus vaccines, attenuated virus vaccines, peptide-based vaccines, and virus-like particle (VLP) vaccines [14–20]. Among these vaccines, the inactivated EV71 vaccine is the most promising, and clinical trials for several vaccines targeting poliovirus have already being tested [19–23]. Inactivated vaccines are considered ideal owing to concerns with the potential for vaccine-derived virulent viruses, e.g., from poliovirus attenuated vaccine [24–26]. In particular, our group recently showed that formalin-inactivated HFMD vaccine using an EV71 strain was a potential candidate vaccine for prevention of EV71 infection [27].

EV71 has a limited host range; only humans can be infected. Thus, a major challenge in EV71 vaccine development is the lack of an animal model for efficacy tests. For preclinical trials of vaccines, animal experiments with mice or nonhuman primates (NHPs) are required. NHP models are more suitable for evaluating the immunogenicity and efficacy of vaccine candidates than mouse models [28] because adult mice are resistant to EV71 infection and suckling mice are hard to manage.

Therefore, in this study, we evaluated the efficacy of the inactivated EV71 vaccine in NHPs, allowing us to analyze potent and long-lasting humoral immune responses. The aim of the present study was to investigate the efficacy of the inactivated EV71 vaccine and to establish a basis for further studies of the protective capacity of the vaccine by challenge with EV71 in NHPs.

Materials and methods

Ethics statement

This study was designed and approved by Korea National Institutes of Health (Experimental approval number: KCDC-024-16-2A). All animal experiments were conducted in strict accordance with the Guidelines of the Institutional Animal Care and Use Committee (KRIIBB-AEC-14126) in the Korea Research Institute of Bioscience and Biotechnology (KRIIBB).

Animals

The monkeys used in the experiment were purchased through formal import procedures from Zhaoqing Laboratory Animal Research Center (Guangdong Province, China) with the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) permit. All animals were maintained at the National Primate Research Center (NPRC) in Korea Research Institute of Bioscience and Biotechnology (KRIIBB). For this study, monkeys were moved to individual indoor cages designed to allow the monkeys to contact each other in vision but avoiding physical touch to prevent contamination. The dimensions of the cages
were 60x80x80cm as per the accordance with the Guide for the Care and Use of Laboratory Animal: Eighth Edition (National Research Council, 2011). To enrich the environment, water, monkey chow (Teklad 2050, Harlan, USA), and various fresh fruits including apples, bananas, and grapes were supplied *ad libitum*. The perches were installed in individual cages. Each primates was given various rubber and plastic toys. If monkeys did not show interest in those toys, toys of different shapes and sizes were put inside the cages. Environmental conditions were controlled with a temperature of 24 ± 2°C, a relative humidity of 50 ± 5%, and a 12:12hr light:dark cycle. The health and behavioral disorders of the monkeys were monitored by animal care staff three times a day. Before and after intervention, the primate veterinarian evaluated vital signs, body weight, clinical signs, and hematological and biochemical values. They were also monitored by microbiological tests including those for B virus, simian retrovirus (SRV), simian immunodeficiency virus (SIV), simian virus 40 (SV40), and simian T-cell lymphotropic virus (STLV), tuberculosis, every year. As all collections of blood samples and vaccine administration were performed under anesthesia, the primates were anesthetized by an intramuscular injection of ketamine (5mg/kg) into the thigh muscle. Blood samples were collected from the femoral vein, and the vaccine was administered to arm muscle. A humane euthanasia procedure was performed by injecting pentobarbital (100 mg/kg) intravenously under the recommendation of the certified veterinarian, if the animal was diagnosed with certain diseases such as unknown fever, and severe diarrhea (containing blood, mucus, and pus), was moribund, or was not eating/drinking and did not show improvement following medication or environmental enrichment.

**Production of inactivated EV71 vaccines**

The KCDC-HFMDV1-EV71 vaccine strain (C4a subgenotype) was isolated from a patient with HFMD in Korea in 2012. The strain was propagated, and viral titers were evaluated in Vero cells (green monkey kidney cells) using Dulbecco’s modified Eagle medium (DMEM). Viral titers were determined by microtitration using Vero cells and expressed as the 50% tissue culture infective dose (TCID$_{50}$), according to the Reed-Muench method. The vaccine strain was inactivated using formaldehyde (Sigma-Aldrich, St. Louis, MO, USA) at 37°C for 5 days and mixed with an equal volume of aluminum hydroxide (InvivoGen, San Diego, CA, USA), which is the most commonly used adjuvant in human vaccines.

**Immunization of monkeys**

Five cynomolgus monkeys (*Macaca fascicularis*), 3 years of age (body weight of 2.88–3.33 kg), were randomly allocated into two groups (G1 and G2); monkeys in the G1 group (n = 3) and G2 group (n = 2) were intramuscularly administrated with 0.5ml of 20 μg of inactivated EV71 vaccine mixed with 2.5 mg alum or phosphate-buffered saline (PBS), respectively. The monkeys in G1 group were boost vaccinated at 4 or 8 weeks after primary vaccination, using the same vaccine. All animals were provided by the National Primate Research Center (NPRC) of Korea. Body weight and temperature of monkeys were measured individually and recorded. Blood samples were collected (1–2 ml) at 0, 3, 7, 12, 28, and 54 weeks after vaccination. Hematological analyses were conducted using an automated hematology analyzer (CELL_DYN 3700; Abbott, IL, USA) according to the manufacturer’s instructions. All animal experiments were conducted in strict accordance with the Guidelines of the Institutional Animal Care and Use Committee (KRB-B-AEC-14126) in the Korea Research Institute of Bioscience and Biotechnology (KIRBB).

**Serum neutralizing assay**

The serum neutralizing (SN) assay was conducted in 96-well microplates containing confluent Vero cells that were seeded 24 h before the experiment. The monkey sera were inactivated at
56˚C for 30 min and stored at -80˚C prior to use. An equal volume of 2-fold serially diluted serum samples was mixed with 50 μL of 100 TCID\textsubscript{50} EV71 (A, B1, B2, B3, B4, C1, C2, C3, C4a, or C5 subgenotypes) and incubated at 37˚C for 2 h. The mixture was applied to a monolayer of Vero cells, which were subsequently incubated at 37˚C for 5 days. The SN titer was determined as the highest dilution that gave no cellular cytopathic effects (CPEs).

**Measurement of EV71-specific antibodies**

EV71-specific IgG antibodies and IgG subclasses in monkey serum were measured by enzyme-linked immunosorbent assays (ELISAs). Ninety-six-well microplates were coated with 100 ng/100 μL of EV71 antigen, and subsequently incubated overnight at 4˚C. After blocking with 100 μL of PBST (PBS containing 0.1% Tween-20) containing 5% skim milk at 37˚C for 1 h, 100 μL of 1:200 test sera in dilution buffer (5% /w/v) skim milk in PBST) was added to each well. After incubation for 1 h, the plates were washed, and a 100-μL aliquot of 1:1000 rabbit anti-monkey IgG diluted in dilution buffer was added. The plates were then incubated at 37˚C for 1 h, followed by the addition of a 100-μL aliquot of 1:5000 horseradish peroxidase (HRP)-conjugated anti-rabbit as the third antibody. After incubation for 1 h at 37˚C, the plates were developed with 100 μL of 3,3′,5,5′-tetra-methylbenzidine (GenDEPOT, Barker, TX, USA) in the dark. The optical density (OD) of the solution was measured at 450 nm. The anti-EV71 IgG subclasses were determined using a human IgG subclass profile kit (Invitrogen Life Technologies, Gaithersburg, MD, USA) according to the manufacturer’s instructions.

**Quantification of cytokine levels using a multiplex system**

For cytokine assays, monkey sera were isolated from blood, and cytokine levels were evaluated following administration of the inactivated EV71 vaccine using a Monkey Cytokine Magnetic 29-plex kit (Life Technologies) on a MAGPIX analyzer system, according to the manufacturer’s instructions.

**Statistical analysis**

Statistical analyses were performed using GraphPad Prism version 5 or InStat3. Data were analyzed using two-way analysis of variance (ANOVA), followed by Bonferroni post-hoc test. Results with P values of less than 0.05 were considered statistically significant.

**Results**

**Clinical signs and hematology of monkeys after EV71 vaccination**

To determine the safety of the inactivated EV71 vaccine, general clinical observations were evaluated. The monkeys administered the inactivated EV71 vaccine were as healthy as monkeys in the mock group. Body weights and body temperatures were not significantly different among groups (data not shown). Significant changes in the numbers of lymphocytes (measured by changes in white blood cells (WBCs), red blood cells (RBCs), platelets (PLTs), and eosinophils) after vaccination were not observed in either group of monkeys (Table 1). These results indicated that the inactivated EV71 vaccine used in this study was safe.

**Immunogenicity of inactivated EV71 vaccine**

To determine whether the inactivated EV71 vaccine could elicit a humoral immune response in NHPs, five cynomolgus monkeys were inoculated with the vaccine, and its immunogenicity was assessed. Humoral immunity was significantly increased in EV71-vaccinated monkeys as compared with those in the mock group (Fig 1A). EV71-specific IgG subclasses were measured
using sera at 12 weeks after vaccination by IgG subclass ELISA. All IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in the vaccinated group were higher than those in the mock group (Fig 1B). The SN antibody titers in the vaccinated group began to increase at 3 weeks after vaccination and remained elevated until 12 weeks; these changes were not detected in the mock group (Fig 2A). The SN antibody titers against the heterologous subgenotypes (A, B1, B2, B3, B4, C1, C2, C3, and C5) were measured using sera at 12 weeks after vaccination (Fig 2B). Among the heterologous subgenotypes, crossreactivity was observed against six subgenotypes (B1, B2, B3, B4, C1, and C5) in the inactivated EV71 vaccine group.

To evaluate cell-mediated immune responses to the inactivated EV71 vaccine, peripheral blood mononuclear cells (PBMCs) from vaccinated monkeys were isolated and used to measure induced cytokines through a multiplex system. Interleukin (IL)-2, IL-12, regulated on activation, normal T cell expressed and secreted (RANTES), C-X-C motif chemokine 10 (CXCL10), hepatocyte growth factor (HGF), IL-4, IL-10, and C-C motif chemokine 22 (CCL22) were induced in vaccinated monkeys compared with those in unvaccinated monkeys (Fig 3). In particular, vaccinated monkeys showed higher levels of IL-2 and IL-12, which are involved in the Th1 immune response, and CCL22, which is involved in the Th2 immune response. These results indicated that the inactivated EV71 vaccine triggered mixed Th1/Th2 immune responses in NHPs. In particular, the Th1 immune response was induced more strongly than the Th2 immune response by the vaccine candidate.

### Immunogenicity of the inactivated EV71 vaccine in a 1-year study

To investigate maintenance of humoral immune responses against the inactivated EV71 vaccine over a 1-year period, serum samples from monkeys were collected at 28 and 54 weeks after vaccination and tested by ELISA and SN assays (Table 2). Compared with the antibody responses of sera from vaccinated monkeys at 12 weeks after vaccination, the longevity of antibody responses was confirmed. Although the antibody titers induced by the inactivated EV71 vaccine were slightly decreased, vaccinated monkeys still exhibited sufficient EV71-specific antibody responses to protect against EV71 at 54 weeks after vaccination. Notably, crossreactivity was observed against six subgenotypes throughout the duration of the experiment (Table 3). These results suggested that the inactivated EV71 vaccine could elicit strong and prolonged EV71-specific antibody responses in monkeys for more than 1 year.

### Discussion

Various approaches, including live-attenuated virus vaccines, inactivated virus vaccines using cell culture systems, VLP vaccines expressed by baculovirus systems in insect cells, subunit vaccines (e.g., viral antigenic protein, synthetic peptide containing epitope sites, and DNA vaccines expressed by mammalian plasmid vectors), have been used to develop an ideal EV71 vaccine to prevent HFMD [14–20]. Safety and long-lasting immunity are the most important characteristic of human vaccines. HFMD vaccines are expected to be safe in young children as vaccine recipients; this is essential because parents are particularly concerned with the safety of vaccines. Clinical trials with EV71 vaccine candidates are currently being tested in China,

---

### Table 1. Hematologic analysis of the monkeys after vaccination with inactivated EV71 vaccine.

| Group | WBC (10⁶/µl) | RBC (10⁶/µl) | PLT (10⁶/µl) | Eosinophil (%) |
|-------|--------------|--------------|--------------|----------------|
| EV71  | 9.05±1.52    | 5.00±0.11    | 592.67±78.13 | 6.03±2.01      |
| MOCK  | 10.06±0.20   | 5.06±0.21    | 451.50±36.50 | 5.32±0.34      |
| Normal| 5.0–21.1     | 4.60–7.30    | 259–734      | 0–10.4         |

https://doi.org/10.1371/journal.pone.0202552.t001
Taiwan, and Singapore in young adults and children [21]. Most of these studies are based on inactivated virus vaccines because of the safety of these vaccines.

HFMD vaccines against EV71 have been developed and studied in mice. Because of the difficulty of using NHPs for in vivo assays, efficacy tests of virus vaccines in NHPs have not been reported frequently. The efficacy of EV71 vaccine candidates was evaluated using NHPs (Taiwan macaques, rhesus macaques, and cynomolgous monkeys) in a few previous studies [15, 29–33]. Most of the efficacy studies of vaccine candidates used NHP models have evaluated inactivated virus and VLP vaccines. Moreover, the safety of inactivated EV71 vaccines has already been confirmed in NHP models and human clinical trials. In this study, the efficacy of inactivated EV71 vaccine candidates composed of a Korean isolate strain belonging to subgenotype C4a was estimated in cynomolgus monkeys. The elicited EV71-specific immune response in monkeys suggested that the vaccine candidate used in this study was safe and well tolerated in NHPs.

EV71 vaccine candidates must be safe and exhibit long-lasting immune responses. In this study, the immunogenicity and safety of an inactivated EV71 vaccine were evaluated in an
Fig 3. EV71-specific cell-mediated immune responses induced by the inactivated EV71 vaccine. Cynomolgus monkeys were vaccinated with inactivated EV71 vaccine (EV71) or PBS (mock) as a control. PBMCs from monkeys were isolated and stimulated with EV71 vaccine. The supernatants of cultured PBMCs were harvested at 24 h after stimulation and analyzed for cytokines using a multiplex system.

https://doi.org/10.1371/journal.pone.0202552.g003
The inactivated EV71 vaccine elicited EV71-specific immune responses and crossreactive antibody responses over the entire 54-week study. These results were consistent with previous studies in which the inactivated EV71 vaccine induced neutralizing antibodies at 33 and 56 weeks after vaccination in macaques [31, 34]. These results suggested that our vaccine candidates could induce long-lasting immune responses in an NHP model.

Due to the diversity of EV71 subgenotypes, it is important for EV71 vaccine candidates to induce crossreactive neutralizing antibody responses against heterologous strains. In this study, we demonstrated that the inactivated EV71 vaccine elicited crossreactive neutralizing antibodies against the heterologous genotypes B and C (B1, B2, B3, B4, C1, and C5). The inactivated EV71 vaccine elicited partial crossreactive neutralizing antibodies to genotype C2 but not to genotypes A and C3. There were amino acid differences between the EV71 vaccine strain and BrCr, A1451, and C3-A strains used in this study, belonging to subgenotypes A, C2, and C3, respectively. These amino acid differences could sufficiently alter conformational changes, particularly epitope sites in the VP1 region. These results suggested that EV71 vaccine strain-specific antibodies capable of crossreactive neutralizing antibodies against different genotypes of EV71 were generated by the vaccine candidate.

In summary, the inactivated EV71 vaccine derived from the C4 strain significantly induced immunogenicity in an NHP model. In particular, the inactivated EV71 vaccine was capable of inducing neutralizing antibody responses in cynomolgus monkeys and crossreactive neutralizing antibodies against heterologous strains belonging to different genotypes of EV71, with the response being maintained for 1 year. These results supported that NHPs were appropriate

### Table 2. Humoral immune response against inactivated EV71 vaccine in monkeys.

| Group   | ELISA test | 12WPV | 28WPV | 54WPV |
|---------|------------|-------|-------|-------|
| EV71    | 1.746±0.05*** | 1.80±0.04*** | 0.87±0.04*** |
| MOCK    | 0.18±0.06 | 0.12±0.04 | 0.08±0.01 |

| Group   | SN assay | 12WPV | 28WPV | 54WPV |
|---------|----------|-------|-------|-------|
| EV71    | 20.3±0.94*** | 14.00±0.82*** | 13.67±0.47*** |
| MOCK    | 0 | 0 | 0 |

* Immunized monkey sera were diluted 1:400 and then used to measure virus-specific antibodies by ELISA.

** Neutralization titers are expressed as the reciprocal of the lowest dilution of antiserum that blocks infection and the mean values and SD are shown.

*** There is a significant difference compared to PBS control group (p<0.001 tested by Two-way ANOVA test).

Neutralization titers was assayed with various enteroviruses indicated in the left and the mean values and SD are shown.

*** There is a significant difference compared to PBS control group (p<0.001 tested by Two-way ANOVA test).
animal models for evaluating EV71 vaccine candidates. Further studies are needed to achieve the development of multivalent vaccines against HFMD, including diverse coxsackieviruses.

**Supporting information**

S1 File. The neutralizing antibody responses by a formalin-inactivated EV71 vaccine in monkey.

(XLSX)

**Author Contributions**

**Conceptualization:** Jung-Ah Lee, Sang-Won Lee.

**Data curation:** Hyun Ju In, Heeji Lim, Jung-Ah Lee.

**Formal analysis:** Hyun Ju In, Heeji Lim, Jung-Ah Lee.

**Investigation:** Hyun Ju In, Heeji Lim, Jung-Ah Lee, Sang-Rae Lee, Yeung Bae Jin, Kang-Jin Jeong.

**Methodology:** Hyun Ju In, Heeji Lim, Jung-Ah Lee.

**Project administration:** Jung-Ah Lee, Ji-Yeon Hyeon, June-Woo Lee.

**Resources:** Hyun Ju In, Heeji Lim.

**Supervision:** Jung Sik Yoo.

**Writing – original draft:** Hyun Ju In, Heeji Lim.

**Writing – review & editing:** Jung-Ah Lee, Young Ki Choi.

**References**

1. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. The Lancet Infectious diseases. 2010; 10(11):778–90. Epub 2010/10/22. https://doi.org/10.1016/S1473-3099(10)70194-8 PMID: 20961813.

2. Cardosa MJ, Perera D, Brown BA, Cheon D, Chan HM, Chan KP, et al. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerging infectious diseases. 2003; 9(4):461–8. Epub 2003/04/19. https://doi.org/10.3201/eid0904.020395 PMID: 12702227; PubMed Central PMCID: PMCPMC2957976.

3. Huang SW, Kiang D, Smith DJ, Wang JR. Evolution of re-emergent virus and its impact on enterovirus 71 epidemics. Exp Biol Med (Maywood). 2011; 236(8):899–908. Epub 2011/07/01. https://doi.org/10.1258/ebm.2010.010233 PMID: 21715436.

4. Yip CC, Lau SK, Zhou B, Zhang MX, Tsoi HW, Chan KH, et al. Emergence of enterovirus 71 "double-recombinant" strains belonging to a novel genotype D originating from southern China: first evidence for combination of intratypic and intertypic recombination events in EV71. Arch Virol. 2010; 155(9):1413–24. Epub 2010/06/16. https://doi.org/10.1007/s00705-010-0722-0 PMID: 20549263.

5. Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974; 129(3):304–9. Epub 1974/03/01. PMID: 4361245.

6. Lum LC, Wong KT, Lam SK, Chua KB, Goh AY, Lim WL, et al. Fatal enterovirus 71 encephalomyelitis. J Pediatr. 1998; 133(6):795–8. Epub 1998/12/08. PMID: 9842048.

7. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999; 341(13):929–35. Epub 1999/09/25. https://doi.org/10.1056/NEJM199909233411301 PMID: 10498487.

8. Yang F, Ren L, Xiong Z, Li J, Xiao Y, Zhao R, et al. Enterovirus 71 outbreak in the People’s Republic of China in 2008. Journal of clinical microbiology. 2009; 47(7):2351–2. Epub 2009/05/15. https://doi.org/10.1128/JCM.00563-09 PMID: 19439545; PubMed Central PMCID: PMCPMC2708525.
9. Lin TY, Twu SJ, Ho MS, Chang LY, Lee CY. Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerging infectious diseases. 2003; 9(3):291–3. Epub 2003/03/20. https://doi.org/10.3201/eid0903.020285 PMID: 12642822; PubMed Central PMCID: PMCPMC2963902.

10. Yip CC, Lau SK, Woo PC, Yuen KY. Human enterovirus 71 epidemics: what's next? Emerg Health Threats J. 2013; 6:19780. Epub 2013/10/15. https://doi.org/10.3402/ehtr.v6i6.19780 PMID: 24119538; PubMed Central PMCID: PMC3772321.

11. Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, Li CC, et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics. 2002; 109(6):e88. Epub 2002/06/04. PMID: 12042582.

12. Chang LY, Hsiung CA, Lu CY, Lin TY, Huang FY, Lai YH, et al. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatr Res. 2006; 60(4):466–71. Epub 2006/08/31. https://doi.org/10.1203/01.pdr.0000238247.86041.19 PMID: 16940249.

13. Lin YW, Wang SW, Tung YY, Chen SH. Enterovirus 71 infection of human dendritic cells. Exp Biol Med (Maywood). 2009; 234(10):1166–73. Epub 2009/07/15. https://doi.org/10.3181/0903-ri-116 PMID: 19596831.

14. Wu C-N, Lin Y-C, Fann C, Liao N-S, Shih S-R, Ho M-S. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001; 20(5-6):895–904. http://dx.doi.org/10.1016/S0264-410X(01)00385-1 PMID: 11738755.

15. Arita M, Nagata N, Iwata N, Ami Y, Suzaki Y, Mizuta K, et al. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol. 2007; 81(17):9386–95. Epub 2007/06/15. https://doi.org/10.1128/JVI.02856-06 PMID: 17567701; PubMed Central PMCID: PMCPMC1951441.

16. Foo DG, Alonso S, Chow VT, Poh CL. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007; 9(11):1299–306. Epub 2007/08/25. https://doi.org/10.1016/j.micinf.2007.06.002 PMID: 17890123.

17. Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008; 26(15):1855–62. Epub 2008/03/11. https://doi.org/10.1016/j.vaccine.2008.01.058 PMID: 18329759.

18. Chung CY, Chen CY, Lin SY, Chung YC, Chiu HY, Chi WK, et al. Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Vaccine. 2010; 28(43):6951–7. Epub 2010/08/28. https://doi.org/10.1016/j.vaccine.2010.08.052 PMID: 20797455.

19. Chou A-H, Liu C-C, Chang J-Y, Jiang R, Hsieh Y-C, Tsao A, et al. Formalin-Inactivated EV71 Vaccine Candidate Induced Cross-Neutralizing Antibody against Subgenotypes B1, B4, B5 and C4A in Adult Volunteers. PLOS ONE. 2013; 8(11):e79783. https://doi.org/10.1371/journal.pone.0079783 PMID: 24278177.

20. Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2013; 381(9882):2024–32. Epub 2013/06/04. https://doi.org/10.1016/S0140-6736(13)60149-1 PMID: 23726161.

21. Chong P, Hsieh S-Y, Liu C-C, Chou A-H, Chang J-Y, Wu S-C, et al. Production of EV71 vaccine candidates. Human Vaccines & Immunotherapeutics. 2012; 8(12):1775–83. https://doi.org/10.4161/hv.21739 PubMed PMID: PMC3656065. PMID: 22992566.

22. Cheng A, Fung CP, Liu CC, Lin YT, Tsai HY, Chang SC, et al. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine. 2013; 31(20):2471–6. Epub 2013/04/02. https://doi.org/10.1016/j.vaccine.2013.03.015 PMID: 23541623.

23. Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, et al. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine. 2012; 30(22):3295–303. Epub 2012/03/20. https://doi.org/10.1016/j.vaccine.2012.03.010 PMID: 22426327.

24. Diamanti E, Ibrahim B, Tafaj F, Mezini E, Dodriba A, Dobi V, et al. Surveillance of suspected poliomyelitis in Albania, 1980–1995: suggestion of increased risk of vaccine associated poliomyelitis. Vaccine. 1998; 16(9–10):940–8. Epub 1998/07/31. PMID: 9682341.

25. Dowdle WR, De Gourville E, Kew OM, Pallansch MA, Wood DJ. Polio eradication: the OPV paradox. Rev Med Virol. 2003; 13(5):277–91. Epub 2003/08/22. https://doi.org/10.1002/rmv.401 PMID: 12931339.

26. Wagner BG, Earm DJ. Circulating vaccine derived polio viruses and their impact on global polio eradication. Bull Math Biol. 2008; 70(1):253–80. Epub 2007/10/16. https://doi.org/10.1007/s11538-007-9255-4 PMID: 17934778.
27. In HJ, Lim H, Lee JA, Kim HJ, Kim JW, Hyeon JY, et al. An inactivated hand-foot-and-mouth disease vaccine using the enterovirus 71 (C4a) strain isolated from a Korean patient induces a strong immunogenic response in mice. PLoS One. 2017; 12(5):e0178259. Epub 2017/05/26. https://doi.org/10.1371/journal.pone.0178259 PubMed Central PMCID: PMCPMC5443535. PMID: 28542556

28. Wang YF, Yu CK. Animal models of enterovirus 71 infection: applications and limitations. Journal of biomedical science. 2014; 21:31. Epub 2014/04/20. https://doi.org/10.1186/1423-0127-21-31 PubMed Central PMCID: PMCPM4013435. PMID: 24742252

29. Dong C, Liu L, Zhao H, Wang J, Liao Y, Zhang X, et al. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine. 2011; 29(37):6269–75. Epub 2011/07/05. https://doi.org/10.1016/j.vaccine.2011.06.044 PMID: 21722686

30. Zhou XB, Lu JJ, Jiang YS, Huo Y, Wang JF, Zhou KF, et al. A safety study of inactivated Enterovirus 71 vaccine. Hum Vaccin Immunother. 2013; 9(7):1430–7. Epub 2013/04/11. https://doi.org/10.4161/hv.23571172

31. Liu CC, Hwang CS, Yang WS, Tsai DC, Wu SH, Chou AH, et al. Long-term immunogenicity studies of formalin-inactivated enterovirus 71 whole-virion vaccine in macaques. PLoS One. 2014; 9(9):e106756. Epub 2014/09/10. https://doi.org/10.1371/journal.pone.0106756 PubMed Central PMCID: PMCPMC4157806. PMID: 25197967

32. Lim PY, Hickey AC, Jamiluddin MF, Hamid S, Kramer J, Santos R, et al. Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates. Vaccine. 2015; 33 (44):6017–24. Epub 2015/08/15. https://doi.org/10.1016/j.vaccine.2015.05.108 PMID: 26271825

33. Zhang Y, Wang L, Liao Y, Liu L, Ma K, Yang E, et al. Similar protective immunity induced by an inactivated enterovirus 71 (EV71) vaccine in neonatal rhesus macaques and children. Vaccine. 2015; 33 (46):6290–7. Epub 2015/10/01. https://doi.org/10.1016/j.vaccine.2015.09.047 PMID: 26419198

34. Lin YL, Yu CI, Hu YC, Tsai TJ, Kuo YC, Chi WK, et al. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine. 2012; 30(7):1305–12. Epub 2012/01/05. https://doi.org/10.1016/j.vaccine.2011.12.081 PMID: 22214866